[1]伍治强** 王洪 曾小飞 李英 何东升 马瑞东 贾维坤.充气式剑突下单孔胸腔镜手术治疗胸腺肿瘤[J].中国微创外科杂志,2022,01(1):59-62.
 Wu Zhiqiang,Wang Hong,Zeng Xiaofei,et al.Inflatable Subxiphoid Singleport Videoassisted Thoracoscopic Surgery for Thymal Tumors[J].Chinese Journal of Minimally Invasive Surgery,2022,01(1):59-62.
点击复制

充气式剑突下单孔胸腔镜手术治疗胸腺肿瘤()
分享到:

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2022年1期
页码:
59-62
栏目:
临床研究
出版日期:
2022-04-07

文章信息/Info

Title:
Inflatable Subxiphoid Singleport Videoassisted Thoracoscopic Surgery for Thymal Tumors
作者:
伍治强** 王洪 曾小飞 李英 何东升 马瑞东 贾维坤
(成都医学院第一附属医院胸心外科,成都610500)
Author(s):
Wu Zhiqiang Wang Hong Zeng Xiaofei et al.
Department of Thoracardiac Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China
关键词:
单孔胸腔镜手术剑突下胸腺肿瘤
Keywords:
SingleportVideoassisted thoracoscopic surgerySubxiphoidThymal tumor
文献标志码:
A
摘要:
目的探讨充气式剑突下单孔胸腔镜手术治疗胸腺肿瘤的可行性和安全性。方法2020年3月~2021年5月我科对20例胸腺肿瘤行充气式剑突下单孔胸腔镜手术,在剑突下2 cm做3 cm横行切口,应用单孔套管穿刺器行充气式单孔胸腔镜手术完整切除胸腺肿瘤。结果20例顺利完成充气式剑突下单孔胸腔镜手术,无中转开胸或增加辅助切口。手术时间平均110 min(60~150 min),出血量平均50 ml(10~80 ml)。前8例胸腔闭式引流管引流平均时间1.5 d(1~3 d),后12例未放引流管。术后病理:胸腺瘤13例,胸腺囊肿5例,胸腺增生2例。20例术后随访1~12个月,中位随访时间6个月,无复发及其他并发症。结论单孔套管穿刺器行充气式剑突下单孔胸腔镜手术治疗胸腺肿瘤简单易行,安全可靠。
Abstract:
ObjectiveTo explore the feasibility and safety of inflatable subxiphoid singleport videoassisted thoracoscopic surgery in the treatment of thymal tumors.MethodsClinical data of 20 cases of thymal tumors in our hospital from March 2020 to May 2021 were retrospectively analyzed. A 3 cm transverse incision was made 2 cm below the xiphoid process, and a singlehole cannula puncture apparatus was applied to carry out inflatable subxiphoid singleport videoassisted thoracoscopic surgery for thymal tumors.ResultsAll the 20 patients underwent inflatable subxiphoid singleport videoassisted thoracoscopic surgery successfully. There was no conversion to thoracotomy or additional assisted incision. Postoperative pathological examination showed 13 cases of thymoma, 5 cases of thymic cyst and 2 cases of thymic hyperplasia. The average operative time was 110 min (range, 60-150 min). The average blood loss was 50 ml (range, 10-80 ml). The average drainage time of closed thoracic drainage tube was 1.5 d (range, 1-3 d) in 8 cases in the first 8 cases, and no drainage tube was placed in the last 12 cases. Postoperative followups lasted for 1-12 months (median, 6 months). There was no relapsing or other complications.ConclusionTreatment of thymal tumors with inflatable subxiphoid singleport videoassisted thoracoscopic surgery is simple to practice, safe and reliable.

参考文献/References:

[1]Kido T, Hazama K, Inoue Y, et al. Resection of anterior mediastinal masses through an infrasternal approach. Ann Thorac Surg,1999,67(1):263-265.
[2]Shi Y, Sun F, Jin Y, et al. Subxiphoid approach with sternum retractor for mediastinal tumor cephalad to brachiocephalic vein. J Thorac Dis,2018,10(6):E473-E475.
[3]Shiomi K, Kitamura E, Ono M, et al.Feasible and promising modified transsubxiphoid thracoscopic extended thymectomy for patients with myasthenia gravis.J ThoracDis,2018,10(3):1747-1752.
[4]Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest,2005,128(4):2893-2909.
[5]Landreneau RJ, Dowling RD, Castillo WM, et al. Thoracoscopic resection of an anterior mediastinal tumor. Ann Thorac Surg,1992,54(1):142-144.
[6]Bril V, Kojic S, Ilse W, et al. Longterm clinical outcome after transcervical thymectomy for myasthenia gravis. Ann Thorac Surg,1998,65(6):1520-1522.
[7]Sugarbaker DJ. Thoracoscopy in management of anterior mediastinal masses. Ann Thorac Surg,1993,56(3):653-656.
[8]Lu Q, Zhao J, Wang J, et al. Subxiphoid and subcostal arch “Three ports” thoracoscopic extended thymectomy for myasthenia gravis. J Thorac Dis,2018,10(3):1711-1720.
[9]Okuda K, Haneda H, Yokota K, et al. Thymothymectomy with pulmonary partial resection using the subxiphoid approach: how to do it? Surg Today,2018,48(12):1096-1099.
[10]伍治强,李庆新,万虹利,等.单孔胸腔镜治疗胸部良性病变18例.中国微创外科杂志,2014,14(3):270-272.

备注/Memo

备注/Memo:
基金项目:成都医学院第一附属医院科研启动基金项目(CYFYGQ26)**通讯作者,Email:woods1008@qq.com
更新日期/Last Update: 2022-04-07